Nav: Home

Early detection, smaller cancer among benefits of skin cancer screening at PCP visits

June 07, 2016

PITTSBURGH, June 7, 2016 - Skin cancer screenings performed by primary care physicians (PCPs) during routine office visits improve the detection of potentially deadly melanomas and find them in earlier stages, according to new research from the University of Pittsburgh School of Medicine.

The results will be presented today at the 52nd annual American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

"Our findings suggest that PCP screening is an effective way to improve early detection of melanoma, which could potentially save lives," said lead author Laura Ferris, M.D., Ph.D., associate professor, Department of Dermatology, Pitt School of Medicine and member of the Melanoma Program, University of Pittsburgh Cancer Institute.

Rates of melanoma, the most dangerous form of skin cancer, are on the rise, and skin cancer screenings are one of the most important steps for early detection and treatment, said Dr. Ferris. Typically, patients receive skin checks by setting up an appointment with a dermatologist.

The goal of the new UPMC screening initiative, which was modeled after a promising German program, was to improve the detection of melanomas by making it easier for patients to get screened during routine office visits with their PCPs, explained Dr. Ferris.

PCPs completed training on how to recognize melanomas and were asked to offer annual screening during office visits to all patients aged 35 and older. In 2014, during the first year of the program, 15 percent of the 333,788 eligible UPMC patients were screened in this fashion.

On average, the melanomas detected in the group who received a screening at a primary care visit were nearly twice as thin as those detected in the group that was not screened by a PCP. Thinner melanomas have a better prognosis than thicker ones that are more advanced, so the new findings suggest PCP screening is able to find melanomas at an earlier, more treatable stage, said Dr. Ferris.

In addition, only 5 percent of people in the screening group had especially worrisome melanomas that were thicker than 1 millimeter--which are more likely to metastasize and require a biopsy of a nearby lymph node -- while 20 percent of the unscreened group did.

"The PCP screenings prevented a lot of people from needing more aggressive therapy. Additionally, we did not see a high rate of false positive biopsies, in which no skin cancer was present, nor did we see a high rate of unnecessary dermatology referrals or skin surgeries, all of which suggest that the program did not simply drive up health care costs needlessly," Dr. Ferris said.

Another important finding was that nearly half of the screened patients were men, who are more likely to get and die from melanoma than women but have been underrepresented in other skin cancer screenings published to date. "It's exciting that our approach improves detection in this especially vulnerable population," said Dr. Ferris.
-end-
Funding for this study was provided by a National Cancer Institute Specialized Program of Research Excellence (SPORE) grant in skin cancer (5P50CA121973-08).

Additional members of the research team included Melissa Saul, M.S., Francis Solano, M.D., Erica Neuren, B.A., Jian-Min Yuan, M.D., Ph.D., and John Kirkwood, M.D., all of UPMC; Martin Weinstock, M.D., Ph.D., of Brown University; and Allan Geller, M.P.H., R.N., of Harvard University.

About UPCI

As the only NCI-designated comprehensive cancer center in western Pennsylvania, UPCI is a recognized leader in providing innovative cancer prevention, detection, diagnosis, and treatment; bio-medical research; compassionate patient care and support; and community-based outreach services. Investigators at UPCI, a partner with UPMC CancerCenter, are world-renowned for their work in clinical and basic cancer research.

http://www.upmc.com/media

University of Pittsburgh Schools of the Health Sciences

Related Melanoma Articles:

Immunity against melanoma is only skin deep
Researchers at Dartmouth's Norris Cotton Cancer Center find that unique immune cells, called resident memory T cells, do an outstanding job of preventing melanoma in patients who develop the autoimmune disease, vitiligo.
Researchers document how melanoma tumors form
University of Iowa researchers have documented in continuous, real time how melanoma cells form tumors.
New driver, target in advanced mucosal melanoma
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.
NIH study reveals how melanoma spreads
Newly identified genes and genetic pathways in primary melanoma -- a type of skin cancer -- could give researchers new targets for developing new personalized treatments for melanoma, and potentially other cancers.
Melanoma research breakthrough gives hope to treatment
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.
Study examines melanoma incidence, death
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.
Research providing promising new treatments for melanoma
In a paper published online Nov. 30, 2016, in Melanoma Management, Adam Riker, M.D., Professor of Surgery and Chief of Surgical Oncology at LSU Health New Orleans School of Medicine, reviews approaches to manage melanoma, including one tested at LSU Health New Orleans that provoked a complete response in a patient with a long history of the disease.
A protein that defines the melanoma blueprint
The latest study of the Melanoma Group at the Spanish National Cancer Research Centre describes the roles of CPEB4; a protein that is crucial for melanoma cell survival.
Nanotechnology supports treatment of malignant melanoma
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology.
Detecting melanoma early, without a biopsy
Colorado State University Professor Jesse Wilson has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.

Related Melanoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...